Literature DB >> 21459809

Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran.

Masoud Etemadifar1, Amir-Hadi Maghzi.   

Abstract

BACKGROUND: The epidemiology of multiple sclerosis (MS) has changed in recent decades.
OBJECTIVES: This study aimed to give an update on the prevalence and incidence of MS in Isfahan, Iran.
METHODS: The study population was all residents of Isfahan province during the period from April 2003 to July 2010. In April 2003, a registry of MS patients was created at the Isfahan MS Society (IMSS), which is the only referral center for MS patients in the province. Nearly all MS patients in Isfahan province are now registered with IMSS and were included in the analysis.
RESULTS: Among the 3522 registered patients, 2716 were female and 806 were male (sex ratio: 3.37 : 1), and 431 were diagnosed in 2009. This results in a prevalence figure of 73.3 (95% CI: 70.9-75.8) and an incidence of 9.1 (95% CI: 8.3-10.0) per 100,000.
CONCLUSION: The reported prevalence and incidence figures in our study were higher than in our previous report of 2007, in which the prevalence and incidence of MS were reported to be 43.8 and 3.64 per 100,000, respectively. This dramatic increase in the prevalence of MS puts Isfahan amongst the regions with the highest prevalence of MS in Asia and Oceania and is mostly due to changing environmental factors, amongst which vitamin D deficiency seems an important factor in our population.

Entities:  

Mesh:

Year:  2011        PMID: 21459809     DOI: 10.1177/1352458511401460

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  42 in total

1.  Prevalence and predictors of depression in Iranian patients with multiple sclerosis: a population-based study.

Authors:  Seyed Mohammad Seyed Saadat; Mozaffar Hosseininezhad; Babak Bakhshayesh; Seyedeh Nastaran Seyed Saadat; Seyedeh Parand Nabizadeh
Journal:  Neurol Sci       Date:  2013-12-10       Impact factor: 3.307

2.  Correlation between heavy metal exposure and GSTM1 polymorphism in Iranian multiple sclerosis patients.

Authors:  Mehdi Aliomrani; Mohammad A Sahraian; Hamid Shirkhanloo; Mohammad Sharifzadeh; Mohammad R Khoshayand; Mohammad H Ghahremani
Journal:  Neurol Sci       Date:  2017-04-21       Impact factor: 3.307

3.  Exposure to UV Wavelengths in Sunlight Suppresses Immunity. To What Extent is UV-induced Vitamin D3 the Mediator Responsible?

Authors:  Prue H Hart; Shelley Gorman
Journal:  Clin Biochem Rev       Date:  2013-02

4.  Dietary Inflammatory Index and Risk of Multiple Sclerosis in a Case-Control Study from Iran.

Authors:  Nitin Shivappa; James R Hebert; Maryam Behrooz; Bahram Rashidkhani
Journal:  Neuroepidemiology       Date:  2016-07-01       Impact factor: 3.282

Review 5.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

6.  Multiple sclerosis in Isfahan, Iran: Past, Present and Future.

Authors:  Masoud Etemadifar; Seyed-Hossein Abtahi
Journal:  Int J Prev Med       Date:  2012-05

7.  Evaluating sex hormone levels in reproductive age women with multiple sclerosis and their relationship with disease severity.

Authors:  Azam Foroughipour; Vajihe Norbakhsh; Sara Hosseinpour Najafabadi; Rokhsareh Meamar
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

8.  Color blindness among multiple sclerosis patients in Isfahan.

Authors:  Vahid Shaygannejad; Khodayar Golabchi; Alireza Dehghani; Fereshteh Ashtari; Sepehr Haghighi; Mahsa Mirzendehdel; Majid Ghasemi
Journal:  J Res Med Sci       Date:  2012-03       Impact factor: 1.852

9.  What is the Real Fate of Vitamin D in Multiple Sclerosis?

Authors:  Vahid Shaygannejad; Zahra Tolou-Ghamari
Journal:  Int J Prev Med       Date:  2013-05

10.  Study of type a and B behavior patterns in patients with multiple sclerosis in an Iranian population.

Authors:  Vahid Shaygannejad; Sedigheh Rezaei Dehnavi; Fereshteh Ashtari; Somayeh Karimi; Leila Dehghani; Rokhsareh Meamar; Zahra Tolou-Ghamari
Journal:  Int J Prev Med       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.